Peer Exchange
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD
4
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
5